Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11313959 | 0.86 | SLC5A2 (0.55) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL2871442 | 0.84 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL15682905 | 0.84 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL15325999 | 0.84 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL38150 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29386304 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1933786 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL29455231 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11MEN1 | |
| SCHEMBL19620374 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14608649 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250121-A1 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| WO-2022007838-A1 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | DONGGUAN HEC NEW DRUG R & D CO., LTD. (CN) | 2022-01-13 | — | — | WO | disclosed |
| EP-3735975-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10759729-B2 | Compounds for treating diabetes | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2020-09-01 | — | — | US | disclosed |
| WO-2020143653-A1 | PREPARATION METHOD FOR GLUCOPYRANOSYL DERIVATIVE AND INTERMEDIATE THEREOF | 广东东阳光药业有限公司 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020129901-A1 | METHOD FOR PREPARING KETONE COMPOUND | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| WO-2020129899-A1 | METHOD FOR PRODUCING C-ARYL HYDROXY GLYCOXIDE DERIVATIVES | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2018-05-10 | — | — | US | disclosed |
| WO-2018011721-A1 | NOVEL POLYMORPHIC FORMS OF ((1S,2S,3S,4R,5S))-2,3,4-(TRIS-BENZYLOXY)-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)PHENYL)-6,8-DIOXA-BICYCLO[3.2.1]OCT-1-YL-METHANOL | GRANULES INDIA LIMITED (IN) | 2018-01-18 | — | — | WO | disclosed |
| EP-3045466-B1 | (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| EP-2069374-B1 | CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2014-07-30 | — | — | EP | disclosed |
| US-8669380-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013068850-A2 | PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN, LTD. (NA) | 2013-05-16 | — | — | WO | disclosed |
| EP-2334687-B9 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2334687-B1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8080580-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8026347-B2 | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010023594-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090030198-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030198-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | SLC2A2, SLC2A1, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885ADRA2A 1593/4885 |
| US-10759729-B2 | Compounds for treating diabetes | SLC5A2, GPR119, DPP4 | SLC5A2 1/4885SLC5A1 4/4885ADRA2A 1995/4885 |
| US-20230250121-A1 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2339/4885 |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1412/4885 |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | GPR119, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 5/4885ADRA2A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.